Abstract:Background: Aberrant chronic inflammation and excess accumulation of lipids play a pivotal role in the occurrence and progression of atherosclerosis. (-)-Epigallocatechin-3-gallate (EGCG), the major catechins in green tea, displayed anti-atherosclerotic properties in vivo and in vitro. However, the effects and underlying mechanism of EGCG on atherosclerosis remain unclear. Methods: Male apolipoprotein E-knockout (ApoE-/-) mice (7 weeks old) fed with high-fat diet (HFD) were treated with normal saline or EGCG (40 mg/kg/d, i.g.) for 18 weeks. Atherosclerotic plaque and liver lipid accumulation were measured by Oil Red staining. Plasma lipids and cytokines were detected using commercial kits. The expression of protein and mRNA was analyzed by western blot and quantitative real-time reverse transcription-polymerase chain reaction, respectively. Results: EGCG administration markedly attenuated atherosclerotic plaque formation in HFD-fed ApoE-/- mice, which were accompanied by increased plasma interleukin-10 (IL-10) level and decreased plasma IL-6 and tumor necrosis factor-α (TNF-α) levels. In addition, EGCG modulated high-fat-induced dyslipidemia, evidencing by decreased total cholesterol (TC) and low-density lipoprotein levels and increased high-density lipoprotein level. Meanwhile, EGCG treatment alleviated high-fat-mediated liver lipid accumulation and decreased liver TC and triglyceride. Mechanistically, EGCG significantly modulated high-fat-induced hepatic tetratricopeptide repeat domain protein 39B (TTC39B) expression and its related genes (Lxrβ, Abcg5, Abcg8, Abca1, Srebf1, Scd1, Scd2, Fas, Elovl5, Mylip) expression in liver from ApoE-/- mice. Notably, EGCG remarkably induced hepatic liver X receptor α (LXRα) and LXRβ expression and inhibited both precursor and mature sterol regulatory element binding transcription factor-1 (SREBP-1) expression. Conclusion: Taken together, our data for the first time suggested that TTC39B was involved in EGCG-mediated anti-atherosclerotic effects through modulation of LXR/SREBP-1 pathway.

(-)-Epigallocatechin Gallate Inhibits Endothelin-1-induced C-reactive Protein Production in Vascular Smooth Muscle Cells.

Epigallocatechin-3-gallate inhibits interleukin-6- and angiotensin II-induced production of C-reactive protein in vascular smooth muscle cells

Epigallocatechin-3-Gallate Inhibits Angiotensin Ii-Induced C-Reactive Protein Generation Through Interfering with the At(1)-Ros-Erk1/2 Signaling Pathway in Hepatocytes

Epigallocatechin-3-gallate Attenuates Lipopolysaccharide-Induced Inflammation in Human Retinal Endothelial Cells

Receptor for Advanced Glycation End Products Involved in Circulating Endothelial Cells Release from Human Coronary Endothelial Cells Induced by C-reactive Protein

Endothelin-1 induces the expression of C-reactive protein in rat vascular smooth muscle cells.

The Inhibitory Effect of (−)-Epicatechin Gallate on the Proliferation and Migration of Vascular Smooth Muscle Cells Weakens and Stabilizes Atherosclerosis

Epigallocatechin-3-gallate Ameliorates LPS-induced Inflammation by Inhibiting the Phosphorylation of Akt and ERK Signaling Molecules in Rat H9c2 Cells

[Epigallocatechin Gallate Attenuates the Expression of Regulated Upon Activation Normal T Cell Expressed and Secreted Induced by Lipopolysaccharide in Human Retinal Endothelial Cells].

Epigallocatechin-3-gallate inhibits angiotensin II and interleukin-6-induced C-reactive protein production in macrophages

(-)-Epicatechin gallate prevented atherosclerosis by reducing abnormal proliferation of VSMCs and oxidative stress of AML 12 cells

(-)-Epigallocatechin-3-gallate Protects Against Uric Acid-Induced Endothelial Dysfunction in Human Umbilical Vein Endothelial Cells

EGCG Attenuates Atherosclerosis Through the Jagged-1/Notch Pathway.

Epigallocatechin Gallate Preserves Endothelial Function by Reducing the Endogenous Nitric Oxide Synthase Inhibitor Level

(-)-Epigallocatechin-3-Gallate Ameliorates Atherosclerosis and Modulates Hepatic Lipid Metabolic Gene Expression in Apolipoprotein E Knockout Mice: Involvement of TTC39B

Epigallocatechin Gallate Preventing Low Density Lipoprotein-Induced Endothelial Dysfunction

(-)-Epicatechin gallate blocked cellular foam formation in atherosclerosis by modulating CD36 expression in vitro and in vivo

Epigallocatechin-3-Gallate Inhibits Matrix Metalloproteinase-9 and Monocyte Chemotactic Protein-1 Expression Through the 67-Κda Laminin Receptor and the TLR4/MAPK/NF-κB Signalling Pathway in Lipopolysaccharide-Induced Macrophages

(-)- <i>Epicatechin Gallate</i> Interferes with Atherosclerotic Lesions by Inhibiting the Foaming of RAW264.7 Cells Induced by ox-LDL

Epigallocatechin Gallate Attenuated the Activation of Rat Cardiac Fibroblasts Induced by Angiotensin II Via Regulating Β-Arrestin1.

Epigallocatechin gallate protects against homocysteine-induced vascular smooth muscle cell proliferation